RecurX Bio's assay captures the most deadly cells from cancer patient biopsies.
The RecurX Bio technology uses a microfluidic device which consists of a series of Y shaped channels. It fits on a microscope slide. A small number of cells from a cancer patient’s biopsy sample are placed in the device. The Y shaped channels mimic the conditions in the body and capture the cells with the phenotypic characteristics that enable them to leave the primary tumor site—those cells that can move, and change their shape to squeeze into progressively smaller channels in the body’s extra cellular matrix and proliferate.
In order for metastatic cancer cells to leave the primary tumor site, they have to be able to move and squeeze into progressively smaller channels in the body's extra cellular matrix and proliferate. RecurX Bio's technology mimics this environment.
By combining migration and proliferation measurements into a composite score, the RecurX Bio technology can with up to 100% accuracy determine and discover drugs that can be used to stop these deadly cells from migrating and proliferating, and predict cancer survival.
RecurX Bio technology captures the most deadly cells
We have early in vitro, animal and human in vivo data in breast cancer, and human in vivo data in glioblastoma. The breast cancer data has been published in Nature Biomedical Engineering in 2019 and the glioblastoma data has been published in Nature Biomedical Engineering in 2020.
See our breast cancer case study of two drugs in clinical trials for breast cancer.